No services found
No Products found
Are you struggling to find a source of custom monoclonal antibodies that selectively bind MHC-peptide complexes? ProteoGenix has the solution. Our team of antibody experts can make your anti-MHC-peptide complex antibody using a range of animal species and services to fit your needs, including custom phage display libraries, single B cell clones, or hybridoma cell lines. Whatever your antibody needs, ProteoGenix will combine its resources, services, and 20 years of expertise to deliver reliable anti-MHC-peptide complex antibodies that consistently perform.
Diverse custom antibody generation strategies
Phage display, hybridoma, single B cell screening. We help you select which custom antibody generation strategy benefits your research and immunotherapy needs.
We guarantee at least 3 unique binders to your antigen.
You get full ownership of the antibody sequences generated!
Take advantage of unique libraries
Get access to our proprietary cancer and auto-immune human phage display libraries. You will find them anywhere else!
Pre-built phage display libraries.
Save time and money by selecting one of our existing libraries from: human (including optionally our cancer and/or auto-immune libraries), rabbits, camelids, dogs.
Naïve or immune library
Choose from our naive libraries or develop your own phage display immune library.
Recombinant antigen production.
Don’t have your target antigen prepped? For best results, we make the antigen needed to isolate your custom anti-MHC antibody.
We update you on every project milestone allowing you to evaluate our progress so we stay on target and on budget.
Fully human antibodies available
Bypass the antibody humanization process and save several weeks by using our existing human library for your immunotherapy needs.
There are three different antibody production strategies ProteoGenix can use to make custom monoclonal antibodies that bind MHC-peptide complexes, also known as TCR-like antibodies. These include hybridoma, B-cell screening, and antibody phage display. ProteoGenix can help you decide which method is most suitable for your project. Allowing ProteoGenix to make your custom anti-MHC antibody means you can choose the monoclonal antibody production discovery service that makes sense for your project and budget.
Choosing between hybridoma development, phage display, and B-cell screening can critically influence the success of your project. Below is a table comparing and contrasting the three antibody production methods we employ to deliver high-performing monoclonal antibodies to our clients.
Antibody phage display involves collecting peripheral blood mononuclear cells (PBMCs) from immunized animal hosts (immune libraries) or unimmunized hosts (naïve libraries). Once PBMCs are collected, the antibody gene segments are converted into cDNA and cloned into a (bacteriophage equivalent of a plasmid) phagemid to make an antibody-phage fusion protein, exposing the antibody to the outer surface of the bacteriophage.
The target antigen is cloned and immobilized so it can bind the target antibody, a process called biopanning. Once bound, the DNA inside the bacteriophage (containing the antibody-related genes) is isolated, sequenced, and expressed to verify the antibody binds antigen with high affinity. Learn more about how using phage display library construction in less than 8 weeks.
Antigen procurement or design and production
Library screening and biopanning
ELISA screening of single phage binders
DNA extraction & antibody sequencing
Recombinant antibody production
Therapeutic antibody production
Stable Cell Line Development
Immune library construction
Antibody phage display is useful for generating monoclonal antibodies to target antigens that traditionally evade most antibody production methods. This includes cancer neoantigens, (such as MHC-peptide complexes), conserved antigens, and human antigens of critical importance. Therefore, if your biomedical research lab or pharmaceutical company is interested in fast-tracking human immunotherapy projects to treat cancer, autoimmunity, or other diseases, then antibody phage display technology is the appropriate method.
Phage display technology has no species limitations. This means you can engineer custom phage display libraries in species ranging from humans to llamas. However, if you are interested in antibodies for clinical use, bypass the time-consuming process of antibody humanization by making your custom naïve library from human PBMCs. This convenience factor makes antibody phage display technology the preferred method to generate immunotherapeutic or diagnostic antibodies.
The other advantage antibody phage display offers over hybridoma and B-cell screening is the benefit of not having to keep fragile cell lines healthy and viable.
There are several ways labs can lose antibody-producing cell lines. The first is from Mycoplasma contamination. Mycoplasma is a slow-growing intracellular bacterium resistant to antibiotics found in cell medium. In fact, 15% to 35% of all cell lines tested are positive for Mycoplasma contamination. This type of biological contamination is notoriously difficult to treat, often destroying the entire cell stock.
Human error is another common reason laboratories lose cell lines. Stocks of cells must be stored long-term in liquid nitrogen. If frozen cell line stocks thaw because of a liquid nitrogen refill mistake then your precious stock of antibody-producing cells is gone.
Phage display overcomes these limitations because fragile cell clones are never produced. Instead, we identify three antibodies that bind your target anti-MHC-peptide complex and deliver the antibody sequences to you. The best part? You retain ownership of the antibody sequences. They are your intellectual property. Thus, you can modify the antibodies for therapeutic purposes or allow ProteoGenix to modify the antibodies for you.
Convert your bench-side discovery into a life-saving bedside therapy using our pre-built human cancer or autoimmunity phage display libraries. ProteoGenix built the world’s first human cancer and human autoimmune phage display libraries to supercharge your immunotherapeutic projects, saving you time, money, and effort.
The process of a healthy cell transforming into a cancer cell is associated with genetic instability that results in the expression of new antigens, termed neoantigens. These cancer neoantigens are presented by MHC-I causing T-cell activation and cancer cell death. However, when a cancer cell evades T-cell detection, uncontrolled cell division occurs triggering the formation if a malignant tumor.
Adaptive antibody responses are mounted against cancer neoantigens, including the cancer cell peptides presented by MHC I. The antibodies that selectively recognize MHC I-cancer peptide complexes are termed TCR-like antibodies.
TCR-like antibodies hold promising immunotherapeutic potential because they selectively bind cancer cells. Therefore, ProteoGenix captured the antibody repertoire from cancer patients in the form of an antibody phage display library to help scientists accelerate their therapeutic and diagnostic cancer projects (read more about TCR-like antibodies below). Therefore, if you discovered a novel MHC-antigen complex, ProteoGenix can generate your clinical monoclonal antibodies from start to finish using our pre-built human cancer library.
One autoimmune disease risk factor is the expression of specific MHC II “risk” alleles by autoreactive antigen-presenting cells (autoAPCs). These MHC II alleles allow the escape of self-tolerance by inadvertently stimulating T-cells when presenting self-antigens.
Although rare, the adaptive immune system can recognize autoantigen presented by MHC II as foreign and build an antibody repertoire to target the MHC II-autoantigen complexes. As in cancer treatment, these TCR-like antibodies have the potential to selectively target and destroy harmful cells including autoreactive APCs.
Therefore, ProteoGenix developed the world’s first naïve human autoimmunity phage display library to help scientists accelerate the discovery of novel anti-MHC-autoantigen complexes for therapeutic and diagnostic applications. Once we identify monoclonal antibody clones that bind your MHC II-autoantigen complex, ProteoGenix can convert it into an antibody-drug complex antibody (ADC) or a bispecific antibody. Therefore, if you discovered a novel MHC-autoantigen complex, ProteoGenix can generate immunotherapeutic monoclonal antibodies from start to finish using our human autoimmune library.
ProteoGenix also offers non-human pre-built naïve antibody phage display libraries. If you are interested in making a custom anti-MHC-peptide complex antibody targeting a non-human MHC then choose from one of the following libraries:
Don’t see a prebuilt library compatible with your research?
Let us make your custom library. Custom libraries give you unlimited access to an array of antibodies that target different MHC-peptide epitopes. This service is perfect for those who know they will need a constant source of antibodies to target yet-to-be-identified MHC-peptide complexes in their disease model.
We can adapt your monoclonal phage display antibody into a bispecific antibody or conjugate it to cytotoxic drugs (ADC antibody) to target diseased tissue. We can also adapt your custom anti-MHC-peptide complex antibody for diagnostic applications such as ELISA, flow cytometry, or clinical imaging.
Generating a hybridoma cell line is a great way to make anti-MHC antibodies that bind MHC-peptide complexes with high affinity. The first step in producing a hybridoma cell line involves immunizing mice or rats with the purified target antigen. Next, we collect splenocytes from the immunized mice or rats and fuse the appropriate B-cells with a myeloma cell line.
We select the hybrid cells by screening the supernatant for antibodies that bind the target antigen by ELISA. Lastly, we subject the positive binders to limited dilutions to isolate individual cells and expanded them into colonies. We then screen each colony and further verify their potential to bind antigen by ELISA. The entire process takes 10 weeks from start to finish. Read more about ProteoGenix’s hybridoma technology
Hybridoma Selection and Screening (Polyclonal Stage)
Isolation of Cell Clones
B-cell screening is a three-step process that produces high-affinity monoclonal antibodies. The first step is a 6- to 8-week process that starts with immunizing rodents with purified antigen assessed by SDS-PAGE. The immunization process has 4-6 rounds of injections using an optimized immunization protocol.
The second step is a 2-3 weeks process involving B-cell sorting and screening. This is achieved by isolating lymphocytes from the PBMC compartment and the spleen of immunized rodents. Lastly, the resulting B-cells are cultured in vitro and the supernatants are assessed for the presence of antibodies that bind the target antigen by ELISA. The resulting best positive antibodies are sequenced cloned, and expressed in XtenCHO cells. Antibody supernatants are further screened by ELISA to confirm the presence of high-quality monoclonal antibodies. Learn more about ProteoGenix’s B-cell screening and isolation methods.
FACS Sorting + ELISA screening
Positive Clones Sequenced and Expressed
Screening of the antibodies produced
Designing monoclonal antibodies that selectively bind MHC-peptide complexes, known as TCR-like antibodies, is a difficult task that few companies attempt. However, our antibody experts use their 25 years of average experience to design and troubleshoot the most daunting antibody eng